SPAC Feed

Sarcomatrix Therapeutics Provides Update on Board Expansion and Rare Disease Programs

The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.

The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.

Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition

VICTORIA, Seychelles, Sept. 14, 2026 (GLOBE NEWSWIRE) — Excent Capital has launched its new website, introducing a redesigned experience for traders, clients and partners worldwide.

U.S. Renal Denervation Devices Market to Reach USD 2.01 Billion and Europe USD 1.13 Billion by 2035 as Ultrasound Catheters, CMS Coverage Review, and Expanding Indications Drive Growth.

U.S. Renal Denervation Devices Market to Reach USD 2.01 Billion and Europe USD 1.13 Billion by 2035 as Ultrasound Catheters, CMS Coverage Review, and Expanding Indications Drive Growth.

MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) — ReleasePad, a Changelog Tool, today launched a Model Context Protocol (MCP) server that lets AI coding agents such as Claude, Codex, Grok and other LLM’s draft, publish and analyze product changelogs directly from a conversation. Release notes are the step most teams skip: the feature ships, the announcement waits, and customers never hear about it. With the MCP server, the same coding agent a developer already works with can close that gap in a sentence: “Look at what we merged this week, draft a release note for customers, and leave it as a draft for me.”

Communiqué de Presse

THE DISSEMINATION, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IS NOT AUTHORIZED IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER COUNTRY WHERE SUCH COMMUNICATION WOULD VIOLATE APPLICABLE REGULATIONS

LA DIFFUSION, LA PUBLICATION OU LA DISTRIBUTION DE CE COMMUNIQUÉ DE PRESSE, EN TOUT OU EN PARTIE, DIRECTEMENT OU INDIRECTEMENT, N’EST PAS AUTORISÉE AUX ÉTATS-UNIS, EN AUSTRALIE, AU CANADA, AU JAPON OU DANS TOUT AUTRE PAYS OÙ UNE TELLE COMMUNICATION VIOLERAIT LES RÉGLEMENTATIONS APPLICABLES

Toronto, Ontario, Sept. 14, 2026 (GLOBE NEWSWIRE) — Belgravia Hartford Capital Inc. (CSE: BLGV) (OTC: BLGVF) (FRA: ECA) (the “Corporation” or “Belgravia”) announces its intention to adopt the policies outlined in the Semi-Annual Reporting (” SAR “) Pilot Program utilizing the exemptions provided under Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the ” Blanket Order “).

As Electricity Costs Reach Historic Highs, Survey from the Virginia Distributed Solar Alliance Highlights Solutions

As Electricity Costs Reach Historic Highs, Survey from the Virginia Distributed Solar Alliance Highlights Solutions

BSN90 is a new 90-credit pathway to a Joyce University BSN, built on rigorous standards and hands-on clinical training

BSN90 is a new 90-credit pathway to a Joyce University BSN, built on rigorous standards and hands-on clinical training

Wellthy acquires Cleo, bringing together two leaders to advance its vision to create the singular platform for family care.

Previously disclosed non-binding LOIs contemplate approximately $240 million in aggregate implied property value across two South Florida multifamily properties totaling approximately 544 units

Previously disclosed non-binding LOIs contemplate approximately $240 million in aggregate implied property value across two South Florida multifamily properties totaling approximately 544 units

On 2 January 2026, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 59 of 18 December 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 240 million during the period 2 January to 31 December 2026. As outlined in Company Announcement no. 48 of 14 August 2026, the programme was extended with up to DKK 170 million, increasing the total amount of which Schouw & Co. will acquire shares to up to DKK 410 million.

Watsco to Expand its Growing Presence in Plumbing Products Distribution by 82 Locations

Watsco to Expand its Growing Presence in Plumbing Products Distribution by 82 Locations